• The technology described in this briefing is RenalSense Clarity RMS. It is used for people in critical care and high dependency care settings who are at risk of developing acute kidney injury (AKI).

  • The innovative aspects are that it automates a step in the care pathway.

  • The intended place in therapy would be as an alternative to an urometer in people with catheters, particularly those at risk of developing AKI or who already have AKI.

  • The main points from the evidence summarised in this briefing are from 1 study (observational) including a total of 63 patients in a general intensive care unit. It shows that RenalSense Clarity RMS is more effective in identifying AKI than using serum creatinine.

  • Key uncertainties around the evidence are that the evidence came from 1 non-comparative observational study done in Israel, which was only a conference abstract.

  • The cost of RenalSense Clarity RMS is £3,810 per unit (excluding VAT), and the sensors cost £65 per person. Standard care, which is a urometer test, costs between £8 and £10.